Anvilab Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 1

Anvilab General Information


Manufacturer of generic pharmaceutical products. The company owns the rights to sell Antigrippin-Maximum, Gepagard, and Inflyunet, pharmaceutical brands and owns the trademark Laborotoria ANVI. It develops life saving drugs for chemotherapy, antiviral and others.

Contact Information

Ownership Status
Financing Status
Corporate Backed or Acquired
Primary Industry
Corporate Office
  • Kashirskoye Sh. 22, Building 4
  • Moscow
  • Russia

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Anvilab Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Anvilab‘s full profile, request access.

Request a free trial

Anvilab FAQs

  • When was Anvilab founded?

    Anvilab was founded in 2007.

  • Where is Anvilab headquartered?

    Anvilab is headquartered in Moscow, Russia.

  • What industry is Anvilab in?

    Anvilab’s primary industry is Pharmaceuticals.

  • Is Anvilab a private or public company?

    Anvilab is a Private company.

  • What is the current valuation of Anvilab?

    The current valuation of Anvilab is 000.00.

  • What is Anvilab’s current revenue?

    The current revenue for Anvilab is 00000.

  • When was Anvilab acquired?

    Anvilab was acquired on 06-Jul-2011.

  • Who acquired Anvilab?

    Anvilab was acquired by Protek (Distribution & Retail).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »